While most studies found that PC surveillance could be cost-effective, the risk thresholds identified for the surveillance to be cost-effective were often higher (e.g. ≥16% prevalence of dysplasia on an EUS in the surveillance population or > 10% lifetime risk of PC) than some of the reported lifetime risks for various moderate PC risk PGVs (e.g. BRCA1, BRCA2, ATM, PALB2, Lynch syndrome). The gene discussed is PALB2; the disease is Lynch syndrome.